Results 21 to 30 of about 8,722 (208)

Carcinoid Heart Disease: How to Diagnose and Treat in 2020?

Clinical Medicine Insights: Cardiology, 2020
Neuroendocrine tumors (NETs, originally termed “carcinoids”) create a relatively rare group of neoplasms with an approximate incidence rate of 2.5 to 5 cases per 100 000 persons.
Barbara Bober, Marek Saracyn, Maciej Kołodziej, Łukasz Kowalski, Elżbieta Deptuła-Krawczyk, Waldemar Kapusta, Grzegorz Kamiński, Olga Mozenska, Jacek Bil   +8 more
doaj   +1 more source

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly

Journal of the Formosan Medical Association, 2016
The aim of the present study was to evaluate the serial changes of GH and IGF-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (LAR) and octreotide LAR.
Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chang   +2 more
doaj   +1 more source

Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?

Genel Tıp Dergisi, 2022
Objective: Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor ...
Çağlagül Erol, Ahmet Volkan Çelik, Özlem Şahin, Gonca Kara Gedik, Hasan Önner, Farise Yılmaz   +5 more
doaj   +1 more source

π‐Extended COUPY Fluorophores for Targeted Near‐Infrared Fluorescence and Lifetime Imaging in Live Cells

Angewandte Chemie, EarlyView.
π‐Extended COUPY dyes, obtained by vinylogation of coumarin‐based COUPY scaffolds, shift absorption, and emission deep into the NIR region while preserving compactness and synthetic accessibility. These bright, photostable dyes enable live‐cell imaging, FLIM, and site‐specific peptide conjugation, offering a modular platform for targeted bioimaging and
Diego Abad‐Montero, Manel Bosch, Rodrigo Garcés‐Castellanos, Michael Q. Schottenhamel, Sergio Pedraza‐Arevalo, Alejandro Ibáñez‐Costa, Justo P. Castaño, Tania García‐Becerra, Elena Rebollo, Marta E. Alberto, Antonio Francés‐Monerris, Vicente Marchán   +11 more
wiley   +2 more sources

Characterization of Somatostatin Receptor Subtype 2 Expression in Stably Transfected A-427 Human Cancer Cells

Molecular Imaging, 2007
Although radiolabeled somatostatin analogs have become highly prevalent in the diagnosis and treatment of somatostatin receptor subtype (sst)-positive tumors, there are relatively few options with respect to sst-positive tumor cell lines and animal ...
Jesse J. Parry, Martin Eiblmaier, Rebecca Andrews, Laura A. Meyer, Ryuji Higashikubo, Carolyn J. Anderson, Buck E. Rogers   +6 more
doaj   +1 more source

Acromegaly: Beyond surgery

Indian Journal of Endocrinology and Metabolism, 2013
Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels.
Gaya Thanabalasingham, Ashley B Grossman
doaj   +1 more source

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

Frontiers in Endocrinology, 2022
Somatostatin exhibits an inhibitory effect on pituitary hormone secretion, including inhibition of growth hormone and adrenocorticotropic hormone (ACTH), and it can have antisecretory and antitumor effects on neuroendocrine tumors (NETs) that express ...
Rosario Pivonello, Pamela N. Munster, Massimo Terzolo, Rosario Ferrigno, Chiara Simeoli, Soraya Puglisi, Utsav Bali, Andreas G. Moraitis   +7 more
doaj   +1 more source

SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.

Folia Histochemica et Cytobiologica, 2010
The effectiveness of the long acting somatostatin analogues like octreotide and lanreotide depends on the expression of specific somatostatin receptors on the target cells.
Jolanta Kunert-Radek, Marek Pawlikowski, Hanna Pisarek, Robert Kubiak, Katarzyna Winczyk   +4 more
doaj   +1 more source

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source